Omaveloxolone
Pre-clinicalRecruiting 0 watching 0 views this week๐ค Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Dec 12, 2024 โ Oct 1, 2029
NCT ID
NCT06623890About Omaveloxolone
Omaveloxolone is a pre-clinical stage product being developed by Biogen for Friedreich Ataxia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06623890. Target conditions include Friedreich Ataxia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03593499 | Pre-clinical | Completed |
| NCT06628687 | Pre-clinical | Recruiting |
| NCT07297199 | Phase 1 | Recruiting |
| NCT07019064 | Phase 1 | Completed |
| NCT06623890 | Pre-clinical | Recruiting |
| NCT06612879 | Phase 1 | Completed |
| NCT06054893 | Phase 1 | Recruiting |
| NCT03664453 | Phase 1 | Completed |
Competing Products
20 competing products in Friedreich Ataxia